Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ContraVir buys fellow antivirals developer Ciclofilin

Executive Summary

Expanding its hepatitis B pipeline, ContraVir Pharmaceuticals Inc. is acquiring fellow antivirals developer Ciclofilin Pharmaceuticals Inc. (developing cyclophilin inhibitors) in exchange for the right to receive future earn-out payments in the form of up to $17mm in cash and up to 10% of ContraVir's issued and outstanding common stock.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies